Dianthus Therapeutics Inc.(DNTH)

$92.28—

Chart

Dianthus Therapeutics Inc.(DNTH)

NASDAQ

$92.28—

Chart Studio

DNTH(DNTH)

DNTH

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.85

Aug 6, 2026 · Reports before open

Revenue Estimate

$297,182

FY2030E EPS$2.96

Analyst Sentiment

Wall St. Consensus

Buy

10 analysts·Moderate coverage

Score

10 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

110%

Buy

990%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$55.00

-39.8%

Consensus

$120.00

+31.4%

Bull

$145.00

+58.8%

12-Month Target Range10 analysts

$55.00$120.00$145.00

Current $91.29Consensus

Current Price

$91.29

Upside to Consensus

$28.71

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+52.92%

EPS—

FY2028

Rev+873.31%

EPS—

FY2029

Rev+967.43%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$1M	$2M	$18M	$189M	$659M
Low	$414,589	$852,064	$8M	$83M	$289M
High	$2M	$3M	$27M	$285M	$995M
EBITDA Avg	$-1M	$-2M	$-18M	$-189M	$-659M
Low	$-2M	$-3M	$-27M	$-285M	$-995M
High	$-414,589	$-852,064	$-8M	$-83M	$-289M
EBIT Avg	$-1M	$-2M	$-18M	$-189M	$-659M
Low	$-2M	$-3M	$-27M	$-285M	$-995M
High	$-414,589	$-852,064	$-8M	$-83M	$-289M
Net Income Avg	$-147M	$-163M	$-160M	$-107M	$112M
Low	$-178M	$-201M	$-223M	$-179M	$30M
High	$-115M	$-126M	$-98M	$-29M	$186M
EPS Avg	$-3.75	$-4.48	$-4.86	$-2.84	$2.96
Low	$-4.72	$-5.31	$-5.89	$-4.73	$0.80
High	$-3.05	$-3.33	$-2.59	$-0.77	$4.93
Analysts (Rev / EPS)	9 / 9	9 / 9	11 / 11	5 / 4	5 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$310,364	$303,182	$374,500	$374,500	$374,500	$374,500	$284,000	$284,000
Low	$303,760	$296,731	$366,531	$366,531	$366,531	$366,531	$277,957	$277,957
High	$330,174	$322,534	$398,404	$398,404	$398,404	$398,404	$302,127	$302,127
EBITDA Avg	$-310,364	$-303,182	$-374,500	$-374,500	$-374,500	$-374,500	$-284,000	$-284,000
Low	$-330,174	$-322,534	$-398,404	$-398,404	$-398,404	$-398,404	$-302,127	$-302,127
High	$-303,760	$-296,731	$-366,531	$-366,531	$-366,531	$-366,531	$-277,957	$-277,957
EBIT Avg	$-310,364	$-303,182	$-374,500	$-374,500	$-374,500	$-374,500	$-284,000	$-284,000
Low	$-330,174	$-322,534	$-398,404	$-398,404	$-398,404	$-398,404	$-302,127	$-302,127
High	$-303,760	$-296,731	$-366,531	$-366,531	$-366,531	$-366,531	$-277,957	$-277,957
Net Income Avg	$-46M	$-53M	$-51M	$-51M	$-53M	$-60M	—	—
Low	$-63M	$-58M	$-56M	$-56M	$-57M	$-65M	—	—
High	$-33M	$-52M	$-50M	$-50M	$-52M	$-58M	—	—
EPS Avg	$-0.95	$-1.11	$-1.07	$-1.07	$-1.10	$-1.25	—	—
Low	$-1.31	$-1.20	$-1.16	$-1.16	$-1.20	$-1.36	—	—
High	$-0.69	$-1.08	$-1.04	$-1.04	$-1.07	$-1.22	—	—
Analysts (Rev / EPS)	7 / 6	4 / 4	4 / 2	3 / 2	3 / 2	3 / 2	2 / 3	5 / 3

Earnings Surprises

Recent Analyst Actions

Jun 10, 2026Jefferies

Dianthus price target raised to $132 from $110 at Jefferies

Target:$132.00

+72.7%from $76.42

May 11, 2026Evercore ISI

Dianthus price target lowered to $120 from $122 at Evercore ISI

Target:$120.00

+35.7%from $88.45

May 6, 2026Raymond James

Dianthus price target raised to $125 from $123 at Raymond James

Target:$125.00

+42.3%from $87.83

Apr 8, 2026Wolfe Research

Dianthus initiated with an Outperform at Wolfe Research

Target:$98.00

+12.0%from $87.48

Mar 9, 2026UBS

Dianthus price target raised to $98 from $81 at Jefferies

Target:$98.00

+23.7%from $79.23

Mar 9, 2026Jefferies

Dianthus Therapeutics (DNTH) PT Raised to $98 at Jefferies

Target:$98.00

+23.7%from $79.23

Mar 9, 2026Robert W. Baird

Dianthus price target raised to $132 from $67 at Baird

Target:$132.00

+66.6%from $79.23

Mar 9, 2026H.C. Wainwright

Dianthus price target raised to $130 from $47 at H.C. Wainwright

Target:$130.00

+64.1%from $79.23

Mar 9, 2026Oppenheimer

Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer

Target:$145.00

+79.3%from $80.88

Mar 9, 2026Stifel Nicolaus

Dianthus Therapeutics (DNTH) PT Raised to $120 at Stifel

Target:$120.00

+48.9%from $80.60

Mar 9, 2026Truist Financial

Dianthus price target raised to $110 from $63 at Truist

Target:$110.00

+38.8%from $79.23

Feb 11, 2026Wedbush

Dianthus price target raised to $55 from $46 at Wedbush

Target:$55.00

+10.7%from $49.70

Jan 29, 2026UBS

Dianthus price target raised to $125 from $62 at Oppenheimer

Target:$125.00

+134.8%from $53.23

Jan 8, 2026Truist Financial

Dianthus price target raised to $63 from $56 at Truist

Target:$63.00

+65.4%from $38.09

Nov 6, 2025Oppenheimer

Dianthus price target raised to $62 from $60 at Oppenheimer

Target:$62.00

+70.0%from $36.46

Oct 14, 2025Truist Financial

Dianthus initiated with a Buy at Truist

Target:$56.00

+62.7%from $34.42

Sep 8, 2025Guggenheim

Dianthus price target raised to $100 from $92 at Guggenheim

Target:$100.00

+215.2%from $31.73

Sep 8, 2025Jefferies

Dianthus gMG data has positive read through to other indications, says Jefferies

Target:$51.00

+60.4%from $31.80

Nov 11, 2024Oppenheimer

Dianthus Therapeutics (DNTH) PT Raised to $52 at Oppenheimer

Target:$52.00

+81.0%from $28.73

Apr 18, 2024Raymond James

Dianthus price target raised to $51 from $34 at Raymond James

Target:$51.00

+111.2%from $24.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance